Pharma major, Lupin’s subsidiary, Lupin Pharmaceuticals Inc has received final approval for its Lamivudine and Zidovudine Tablets, 150 mg/300 mg from the United States Food and Drugs Administration (FDA). Lupin has already commenced shipping the product.
Lupin’s Lamivudine and Zidovudine Tablets are the AB rated generic equivalent of Viiv Healthcare’s Combivir Tablets, 150/300 mg. Combivir Tablets, had annual US sales of approximately $27.5 crore for the twelve months ending December 2011 (IMS Health Sales Data).
Lamivudine Zidovudine is a combination of two nucleoside analogue reverse transcriplase inhibitors and is indicated in combination with other antiretroviral agents for the treatment of HIV-1 infection.
